1-2 of 2
Keitaro Fukuda
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

IFNγ score–based neoadjuvant immunotherapy for stage III melanoma

Keitaro Fukuda
Journal: Journal of Experimental Medicine
J Exp Med (2023) 220 (5): e20230160.
https://doi.org/10.1084/jem.20230160
Published: 15 March 2023
View article titled, IFNγ score–based neoadjuvant immunotherapy for stage III melanoma
Open the PDF for IFNγ score–based neoadjuvant immunotherapy for stage III melanoma in another window
Journal Articles

AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma

In Special Collection:
The Inflammasomes: From Mechanism to Therapeutics , JEM Cancer Immunotherapy 2021
Keitaro Fukuda, Ken Okamura, Rebecca L. Riding, Xueli Fan, Khashayar Afshari, Nazgol-Sadat Haddadi, Sean M. McCauley, Mehmet H. Guney, Jeremy Luban, Takeru Funakoshi, Tomonori Yaguchi, Yutaka Kawakami, Anastasia Khvorova, Katherine A. Fitzgerald, John E. Harris
Journal: Journal of Experimental Medicine
J Exp Med (2021) 218 (9): e20200962.
https://doi.org/10.1084/jem.20200962
Published: 29 July 2021
View article titled, AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma
Open the PDF for AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma in another window